TNFRSF17 and Miyoshi myopathy: However, most of the focus on the BAFF/APRIL/BCMA axis in MM has been on BCMA as a major target of interest as evidenced by work on three immunotherapy fronts [123]: as a monoclonal ADC, as a component of the bispecific T-cell engager (BiTE) strategy (see Section 7), and in conjunction with chimeric antigenic receptor-T cell (CAR-T) therapy [124,125].